Nouvelles
Découvrez les dernières nouvelles et les développements en IA et en apprentissage automatique dans le domaine de la thérapie guidée par imagerie (TGI) au Canada.
INOVAIT et le gouvernement du Canada investissent 10,7 millions de dollars dans des technologies de thérapie guidée par imagerie améliorées par l’IA
June 14, 2024 | Toronto, ON – Today, INOVAIT and the Government of Canada announced a $10.7 million investment in contributions to seven commercialization-focused R&D projects under the second iteration of INOVAIT’s Focus Fund program. Founded by the Sunnybrook Research Institute (SRI) and supported by the Government of Canada’s Strategic Innovation Fund (SIF), INOVAIT is Canada’s network focused on advancing image-guided therapy (IGT) through the integration of artificial intelligence (AI), big data, and machine learning. IGT is the practice of using medical imaging to plan, perform, and evaluate medical interventions. The INOVAIT network supports Canadian innovators who are unleashing the…
Nouvelles du réseau
2024 Discovery Forum Recap
Last week, we hosted our 3rd annual Discovery Forum and welcomed our esteemed members from across the country to Torys...
Tenomix secures oversubscribed $2.1M, all-Canadian financing round to advance cancer staging
Tenomix, an image-guided diagnostic company based out of Western University’s BioNext Medtech Incubator, recently celebrated a significant milestone with an oversubscribed all-Canadian $2.14M funding round. Established in 2021 by four alums of WORLDiscoveries’ Medical Innovation Fellowship program at Western University, Tenomix is transforming cancer staging, particularly in colorectal cancer, with its innovative approach.
PulseMedica is laser-focused on tackling vitreoretinal diseases
The PulseMedica platform is a 3D image-guided therapy device that integrates powerful laser therapy, advanced medical imaging, and limitless machine learning (ML) for precision imaging and treatment of vitreoretinal disease. Vitreoretinal diseases exist within the clear gel (vitreous fluid) that fills the eye and retina at the back of the eye. PulseMedica’s device strives to automate the imaging and treatment process, enabling quick and precise disease targeting, thereby reducing the treatment time and reducing the risk of side effects and total time per patient, allowing for more patients to be treated each day.
Sonic Incytes is making liver screening more accessible
Sonic Incytes, a Canadian artificial intelligence (AI)-assisted medical imaging company based out of Vancouver, British Columbia, is looking to change the way liver disease is screened and monitored globally. Their flagship, FDA cleared device, Velacur™, is revolutionizing the diagnosis and management of chronic liver disease. Their proprietary technology that grew into Velacur was originally developed by researchers at the University of British Columbia (UBC).
Série de conférences sur la TGI
Regulating AI in Image-Guided Therapy
Suivre INOVAIT sur les médias sociaux